Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …

Nanoparticle polymeric micellar paclitaxel (Pm-Pac) has been demonstrated to have a
safety profile and efficacy in advanced non-small cell lung cancer (NSCLC) patients …

Abstract Background Circulating tumour DNA (ctDNA)-based sequencing might provide a
simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to …

Background Nanocarrier platforms have been indicated to have great potential in clinical
practice to treat non-small cell lung cancer (NSCLC). Our previous Phase III clinical study …

Objective To facilitate immunotherapy and prognostic assessment of non-small cell lung
cancer (NSCLC), we established a novel immunogenomic classification to provide valid …

That impairment of immune response may actually play an active role in the development of
NSCLC, it is well anticipated by the beneficial effects of tumor lymphocytic infiltration on the …

Dear Editor, In our previous study (NCT03628521), the efficacy and safety of sintilimab plus
anlotinib regime have been evaluated upon the patients with advanced non-small cell lung …

Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer with
heterogeneous outcomes and diverse therapeutic responses. However, the understanding …

Anlotinib has been demonstrated to be effective in advanced non‐small cell lung cancer
(NSCLC) patients. The response stratification of anlotinib remains unclear. In this study …

Nanoplatform-based drug delivery plays an important role in clinical practice. Polymeric
micellar (Pm) nanocarriers have been demonstrated to reduce the toxicity of paclitaxel in …